위딩스 바디 스캔 2

Existing home scales only measure weight or body fat, showing only a fragmented view of health. The risk of chronic diseases such as diabetes and hypertension had to rely on hospital checkups, and it was difficult for patients to continuously monitor their health at home. In particular, the elderly or those at risk of chronic diseases often deteriorated between hospital visits and tests. Meanwhile, hospitals also had difficulty receiving patient data from home for early intervention.

In short,"It is difficult to easily recognize and take action on major health risk signals at home."was the problem. Although there are individual devices such as blood pressure monitors and blood glucose meters, they must be used separately, and it is difficult to grasp comprehensive health trends at a glance. Due to these limitations, patients miss opportunities to take action before their conditions worsen, and healthcare providers lose opportunities for real-time monitoring.

Body Scan 2 goes beyond a simple scale andfunctions as a "home health hub."It is the world's first scale to use AI to calculate the risk of developing diabetes, hypertension, and heart failure. This is possible because Withings' medical AI analyzes over 60 biomarkers, including arterial stiffness, ECG, nerve health, and cellular metabolic efficiency, by integrating bioimpedance analysis of the feet/legs, a handle-integrated ECG sensor, and an optical PPG sensor, and then provides risk scores for the three major chronic diseases.

Previously, such risk prediction was only possible through hospital checkups, but Body Scan 2 realizes this with just 90 seconds of measurement on the platform. In addition, it has a built-in remote patient monitoring (RPM) function that allows early action by automatically notifying the doctor when the predictive AI algorithm monitors the user's health trends and shows signs of deterioration. It is also differentiated by the fact that it is equipped with a cellular communication module and a 15-month lasting battery, so that even the elderly can use it without the hassle of Wi-Fi setup or charging.

In a word, Body Scan 2 is"a comprehensive solution that obtains professional-level data at home, interprets it with AI, and is linked to healthcare professionals"and is on a different level from existing smart scales.

Both consumers interested in health management (B2C) and medical institutions seeking to introduce telemedicine (B2B) can become customers. First of all, health and fitness enthusiasts, Withings' traditional customer base, and individuals in their 40s and 60s who are concerned about the risk of chronic diseases are likely to purchase it as a premium product.and 원격 의료를 도입하려는 의료 기관 (B2B) 모두가 고객이 될 수 있다. 우선 Withings의 전통적인 고객층인 건강 및 피트니스 애호가, 만성질환 위험을 걱정하는 40~60대 개인들이 프리미엄 제품으로 구매할 가능성이 높다.

In addition, Body Scan 2 can also be used as a patient monitoring platform, so a B2B2C model is expected in which medical service providers or insurance companies provide it to patients to collect data. For example, hospitals/clinics can provide this device to patients with hypertension or diabetes to collect data and use it for consultations at home, or insurance companies can distribute it to subscribers as part of a health promotion program. Since the price is higher than that of ordinary scales, it is expected that it will be introduced mainly by premium individual consumers and healthcare companies in the early stages, and the degree of popularization will be determined by economies of scale and insurance coverage in the future.

Body Scan 2 is a product targeting the global healthcare market, and is currently awaiting FDA approval in the United States and is scheduled to be released in North America and Europe in 2026. From a regulatory perspective, Withings has already built trust through European CE certification, etc., although it must obtain certification in each country for some medical device indicators (e.g., hypertension risk score, etc.). Therefore, it can be sold worldwide once regulatory approval is obtained.

In addition, in line with the telemedicine trend, it can be developed in a form that is linked to the medical system, so it has high scalability. For example, it can be used as a module of a digital health platform through API linkage with other health apps or EMR (electronic medical records). Expansion into other industries includes insurance discount linkage (insurance premium benefits depending on health score) or fitness coaching service linkage, and above all, since "if you have one at home, the whole family can monitor their health," it has the potential to become an essential smart device for the home. The price is still high at around $599, but it is likely to expand to entry-level models over time.

In summary, Body Scan 2 has considerable potential for market expansion in terms of medical system and technological development trends.

The response from experts has been enthusiastic, with praise such as *"the reinvention of the scale."* In addition to winning the CES Innovation Award, many media outlets have highlighted this product. Tom's Guide was greatly impressed, saying that "they gained a wealth of wellness insights in 90 seconds," and Fox News included Body Scan 2 in its list of notable health tech at CES 2026. In particular, Tom's Guide said,"the first smart scale to give high blood pressure risk alerts after smartwatches"emphasizing that it is an unprecedented function.

Regarding the completeness of the technology, a reporter stepped on it directly at the CES site and said,"It provides detailed data, even telling you your foot vascular age,".and was amazed. Of course, there are criticisms that the price of $599 is high compared to market expectations, and there are cautious opinions that additional verification by the medical community is needed compared to the accuracy of professional medical devices. However, overall, the evaluation of *"a game changer in home wellness devices"* is dominant, and expectations for reliability are high because it uses technically proven sensors. As FDA approval is imminent, it is expected that there will be great interest and initial demand at the time of launch.